Nateglinide · more major-labeled pairs than Octreotide
SPL labels Nateglinide + Octreotide as minor; Nateglinide 8 / Octreotide 5 in that band.
Mechanism on file: Octreotide can reduce the blood-sugar-lowering effects of nateglinide. This may lead to higher blood sugar levels than normal.
FDA SPL severity: Minor
Nateglinide + Octreotide · SPL mechanism field
Octreotide can reduce the blood-sugar-lowering effects of nateglinide. This may lead to higher blood sugar levels than normal.
Minor band excerpt · Nateglinide with Octreotide
Drugs and Herbals That May Reduce the Blood-Glucose-Lowering Effect of Nateglinide and Increase Susceptibility to Hyperglycemia Drugs: Thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin, somatostatin analogues (e.g., lanreotide, octreotide), and CYP inducers (e.g., rifampin, phenytoin and St John's Wort).
Nateglinide · 1 major-labeled pairs (vs Octreotide's 0)
- Amiodarone minor
- Clonidine minor
- Fluconazole minor
- Leflunomide minor
Octreotide · 14 SPL pairs (broader portfolio than Nateglinide)
- Bromocriptine minor
- Cyclosporine minor
- Glucagon minor
- Repaglinide minor
FDA Drug Labels (SPL) via openFDA. Registry display only. Not medical advice.
Read our methodology - how this data is sourced, computed, and verified.